Close Menu

NEW YORK – Researchers at Washington University School of Medicine in St. Louis have used mass spectrometry as part of a study to obtain accurate measurements of amyloid beta, a protein biomarker for Alzheimer's, to predict whether the protein has accumulated in the brain.

When blood amyloid levels are combined with two other major Alzheimer's risk factors —age and the presence of the genetic variant APOE4 — people with early Alzheimer's brain changes can be identified with 94 percent accuracy, the study found.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.